Thank you for standing by, and welcome to the Q4 2021 SLR Investment Corp Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to Michael Gross, Chairman and Co-CEO. Please go ahead. Thank you, operator, and good morning. Welcome to SLR Investment Corp's earnings call for the fiscal year ended December 31st, 2021. I'm joined here today by Bruce Spohler, our Co-Chief Executive Officer, and Richard Peteka, our Chief Financial Officer. Rich, before we begin, would you please start by covering the webcast and forward-looking statements? Of course. Thanks, Michael. I would like to remind everyone that today's call and webcast are being recorded. Please note that they are the property of SLR Investment Corp, and that any unauthorized broadcasts in any form are strictly prohibited. This conference call is being webcast from the Investors tab on our website at www.slrinvestmentcorp.com. While your replays of this call will be made available later today, as disclosed in our earnings press release. I would also like to call your attention to the customary disclosures in our press release regarding forward-looking information. Statements made in today's conference call and webcast may constitute forward-looking statements which relate to future events or our future performance or financial condition. These statements are not guarantees of our future performance, financial condition or results, and involve a number of risks and uncertainties, including impacts from COVID-19. Past performance is not indicative of future results. Actual results may differ materially as a result of a number of factors, including those described from time to time in our filings with the SEC. SLR Investment Corp undertakes no duty to update any forward-looking statements unless required to do so by law. To obtain copies of our latest SEC filings, please visit our website or call us at 212-993-1670. Comments on today's call include forward-looking statements reflecting our current views with respect to, among other things, the timing and likelihood of the merger closing, the expected synergies and savings associated with the merger, the ability to realize the anticipated benefits of the merger, our future operating results and financial performance, and the payment of dividends going forward. Please specifically note that the amount and timing of past dividends and distributions are not a guarantee of any future dividends or distributions or the amount thereof, the payment timing and amount of which will be determined by SLR Investment Corp's board of directors. At this time, I'd like to turn the call back to our Chairman and Co-CEO, Michael Gross. Thank you very much, Rich. Good morning and thank you for joining us. The fourth quarter of 2021 culminated a record year of originations for SLRC, having originated $1.1 billion of investments which translated into net portfolio growth for the year. Against the backdrop of the continued economic rebound and record levels of private equity and leveraged finance activity, our pipeline has been robust. During the quarter, we originated $340 million of new investments following strong third quarter originations. This is one of our most active quarters in recent years. We've been able to remain highly selective while generating portfolio growth. Net asset value per share for the fiscal year ended December 31st with $19.93. For the fourth quarter of 2021, SLRC earned net investment income of $0.35 per share. Overall, portfolio credit quality remains strong, with only one investment on non-accrual. Due to our focus on upper middle market companies in defensive sectors, the effects of rising inflation and supply chain disruptions in our portfolio have been muted. Thus far, we have seen no impact on our portfolio companies of the economic consequences resulting from the Russian invasion of Ukraine, as our company's operations are largely tied to the U.S. economy. We are, however, closely monitoring the economic impacts of this evolving crisis. At December 31st, over 99% of our comprehensive investment portfolio, which takes into account the loan portfolios of SLRC subsidiaries, was invested in senior secured loans, and 79% of its portfolio's fair value was allocated to specialty finance investments. Our most recent commercial finance acquisition, Kingsbridge, is performing above our expectations. Our other specialty finance subsidiaries continue to regrow the portfolios following their trough utilization levels resulting from government stimulus and other COVID-induced challenges. At December 31st, SLRC's leverage was 0.97x net debt to equity, compared to 0.56 x net debt to equity at September 30th, 2020, when our leverage hit its lowest point during the pandemic. The increase represents progress in rebuilding our portfolio from its pandemic low. During the fourth quarter, we amended our senior secured credit facility. The amendment includes a reduction in the credit facility's pricing grid of 25 basis points to LIBOR plus 175 basis points - 200 basis points. The credit facility was expanded from $620 million- $700 million and was extended by two years until December 2026. Additionally, the amendment enhanced our flexibility. In January of 2022, we issued $135 million of 3.3% senior unsecured notes due January 2027 in a private placement. Through this $135 million issuance, together with the $50 million of senior unsecured notes issued in Q3 2021, we have lowered the company's long-term average unsecured financing rate. The $185 million of senior unsecured notes due 2027 have a weighted average interest rate of 3.2%, a significant reduction from the 4.5% weighted average interest rate on the $150 million of senior unsecured notes that are due this May. Looking forward, we expect to deploy our low-cost available capital towards investments across our lending strategies. The breadth of our investment strategies means that we only need to see modest growth from our verticals to drive meaningful portfolio growth and earnings growth. In addition, we have an active pipeline of tuck-in and new specialty finance platform acquisition opportunities. As we announced in December, SLRC has entered into an agreement to merge with SUNS, also managed by SLR Capital Partners, with SLRC as a surviving company, subject to shareholder approval and customary closing conditions. The board of directors of both SLRC and SUNS, on the recommendation of special committees consisting only of the independent directors, have unanimously approved the acquisition. We believe the transaction with SUNS makes strategic sense for the company and will create long-term value and growth opportunities for SLRC shareholders for a number of reasons, a few of which I'll highlight now. The greater scale of the combined company should provide several benefits. As of December 31st, the combined company would have approximately $2.1 billion of total assets and $1.1 billion of net assets, with a larger market capitalization that is expected to provide greater trading liquidity, garner additional institutional investor interest and research coverage, and enhance the company's access to equity and debt markets. Additionally, the greater scale will increase portfolio diversification, as well as to expand the opportunity set for additional commercial finance opportunities to include large investments and asset purchases. Upon closing, SLR Capital Partners, the investment advisor to SLRC, has voluntarily agreed to a permanent 25 basis point reduction of the annual base management fee from 1.75% - 1.5% gross assets. The contractual step-down base management fee to 1% on gross assets above 1:1 leverage will remain in place. The business combination is expected to be accretive to net investment income per share. Based on SLRC's and SUNS' balance sheet at December 31st, 2021, the pro forma leverage for the combined entity would have been approximately 0.9x, translating to only a slight reduction in SLRC's leverage. Over time, we expect that a combination of expected cost savings, reduced base management fees, and interest savings resulting from more efficient debt financing should drive net investment income growth. Importantly, it's anticipated that the larger scale and capital base should allow the combined company to grow NII faster than either SLRC or SUNS would be able to achieve on a standalone basis and to potentially generate higher net investment income per share. At this time, I'll turn the call over back to our CFO, Rich Peteka, to take you through the fourth quarter financial highlights. Thank you, Michael. SLR Investment Corp's net asset value at December 31st, 2021 was $842.3 million, or $19.93 per share, compared to $853.5 million, or $20.20 per share at September 30th, 2021. At December 31st, 2021, SLRC's on-balance sheet investment portfolio had a fair market value of $1.67 billion in 106 portfolio companies across 34 industries, compared to a fair market value of $1.62 billion in 106 portfolio companies across 33 industries at September 30th, 2021. At December 31st, 2021, the company had $818.5 million of debt outstanding, with leverage of 0.97 x net debt to equity. When considering available capital from the company's credit facilities, together with available capital from the non-recourse credit facilities at SLR Credit Solutions, SLR Equipment Finance, and Kingsbridge, SLR Investment Corp has significant available capital to fund future portfolio growth. Moving to the P&L, for the three months ended December 31st, 2021, gross investment income totaled $35.7 million, versus $32.2 million for the three months ended September 30th, 2021. Expenses totaled $20.8 million for the three months ended December 31st, 2021. This compared to $17.2 million for the three months ended September 30th. Included in this quarter's expenses were $0.9 million of one-time costs associated with the merger with SLR Senior Investment Corp. Importantly, due to where SLRC is in its incentive fee catch-up, these expenses were effectively incurred by the manager and not by our shareholders. Accordingly, the company's net investment income for the three months ended December 31st, 2021 totaled $14.9 million, or $0.35 per average share, compared to $15.0 million, or $0.36 per average share, for the three months ended September 30th. Below the line, the company incurred net realized and unrealized losses for the fourth fiscal quarter totaling $8.8 million, versus net realized and unrealized losses of $1.6 million for the third quarter of 2021. Ultimately, the company had a net increase in net assets resulting from operations of $6.1 million, or $0.14 per average share for the three months ended December 31st, 2021. This compares to a net increase of $13.4 million, or $0.32 per average share for the three months ended September 30th. Finally, our board of directors declared a Q1 2022 distribution of $0.41 per share, payable on April 1st, 2022, to shareholders of record on March 18th, 2022. Following the closing of the proposed merger with SLR Senior Investment Corp, SLRC's board of directors intends to begin declaring monthly distributions instead of quarterly. With that, I'll turn the call over to our Co-CEO, Bruce Spohler. Thank you, Rich. SLRC's strong portfolio performance supports our underwriting thesis of investing at the top of the capital structure in first lien cash flow loans to upper mid-market financial sponsors in non-cyclical industries, and allocating a significant portion of our exposure to collateralized loans to our specialty finance verticals. At year-end, our comprehensive portfolio was just over $2 billion and remained highly diversified, encompassing over 600 distinct borrowers across 75 industries. Our largest industry exposures continue to be healthcare services, diversified financials, life sciences, and recurring software. At year-end, over 99% of the portfolio consisted of senior secured loans. 94% was invested in first lien assets, and only 5% was invested in second lien. Of the second lien loans, roughly half were cash flow or 2.4% of the portfolio, and roughly 2.8% were asset-based second lien loans with full borrowing base. At year-end, our weighted average asset level yield was 10%. By focusing on our commercial finance verticals, we've been able to maintain blended asset level yields around 10% despite a decrease in LIBOR and recent spread compression. Notably, we've been able to maintain these yields while actively reducing our exposure to second lien cash flow investments. At year-end, the weighted average investment risk rating was under two, based on our one to four risk rating scale, with one representing the least amount of risk. Total originations for the fourth quarter were $340 million, and repayments were just over $260 million. In addition, we had approximately $150 million of unfunded commitments outstanding at year-end, which we expect to fund in future quarters. Now, let me provide an update on each of our investment verticals. SLR Sponsor Finance. Our sponsor cash flow portfolio was $440 million, or approximately 21% of the comprehensive portfolio, and is invested across 23 borrowers. The average EBITDA of our cash flow investments was approximately $85 million, which is consistent with our focus on larger upper mid-market borrowers. During the fourth quarter, a compelling set of cash flow opportunities across healthcare software and financial services industries drove our originations. We originated $56 million in the fourth quarter of new and existing investments. As Michael mentioned, we've been able to take advantage of the broader scale of the SLR platform to underwrite larger investment positions in first lien cash flow loans to upper mid-market sponsor-owned companies. Given the sponsor community's preference for partnering with just a couple of lenders, each with large investment sizes, SLRC would not be able to participate in these financings without the capacity of the broader SLR platform to co-invest alongside SLRC. Recent commitments have grown to over $200 million on a given investment, which demonstrates the benefit of our platform's ability to speak for larger transactions. We've also increased our commitments to delayed draw term loans which are issued by borrowers to fund future acquisitions. These transactions offer a prudent opportunity for SLRC to grow its investments and establish credits with existing financial covenant packages. At year-end, the weighted average yield of our cash flow portfolio was just over 8%. Now let me turn to our asset-based lending vertical, Credit Solutions. At year-end, this portfolio was $440 million, or approximately 21% of our total portfolio across 23 distinct borrowers. The weighted average asset level yield of this portfolio was 11.5%. In the fourth quarter, we originated $105 million of new asset-based investments and had repayments of just under $70 million. Credit Solutions' ability to assess and monitor collateral makes it an attractive financing partner during periods of economic stress when banks tend to pull back. Therefore, this business provides counter-cyclicality to our broader platform. We are also seeing greater demand from commercial finance businesses for working capital as well as growth capital, a lending strategy that our team has significant expertise in. For the quarter, SLR Credit Solutions paid a cash dividend of $5.5 million, consistent with the prior quarter. Now let me turn to our leasing business, Kingsbridge. We are now over a year into the investment in Kingsbridge and are thrilled with our results. The credit quality of their portfolio remains strong, and originations during 2021 were steady. At year-end, their highly diversified portfolio of leases across three equipment sectors, which include technology, industrial sectors, and healthcare, totaled just over $575 million, with an average funded exposure of just over $1.25 million per obligor. This lease portfolio was 100% performing at year-end, with the majority of Kingsbridge assets being leased by investment-grade borrowers. For the fourth quarter, Kingsbridge paid a dividend of $3.5 million to SLRC, consistent with the prior quarter and equating to the 10.2% annualized yield on cost. Including the interest on our loan investment in Kingsbridge of $80 million, gross income generated for the fourth quarter was $5.2 million. We expect to see Kingsbridge portfolio expand during 2021 as a result of their sizable pipeline. Now let me turn to Equipment Finance. As a reminder, included in our Equipment Finance segment are financings held directly on our balance sheet, as well as those held in our subsidiary, SLR Equipment Finance, for tax efficiency purposes. In the fourth quarter, Equipment Finance invested just under $60 million and had repayments of just over $40 million. At year-end, the portfolio totaled $336 million and was invested across 83 different borrowers with an average exposure of $4 million. This asset class represented 16% of our total comprehensive portfolio. A reminder, 100% of these investments are first lien. The weighted average asset level yield was 9.5%. During the fourth quarter, our comprehensive investment income across Equipment Finance was just under $4 million. The rebound in economic activity that started in the second half of last year and continued throughout into this year has been supportive of the performance of our Equipment Finance portfolio. We are seeing equipment valuations return to pre-COVID levels and improvement in the underlying credit quality of the borrowers. Our team expects to grow this portfolio this year. Life Sciences. At year-end, our portfolio totaled just over $270 million, consisting of 15 borrowers. All of our borrowers in this asset class are currently exceeding expectations relative to at the time of underwriting. Life science loans represent 13% of the comprehensive portfolio, yet contributes 21% of our gross investment income during that quarter. The life science team committed over $120 million during the fourth quarter, of which $66 million was new originations. Repayments and amortizations totaled $31 million. During the pandemic, our life science portfolio experienced lighter churn than is typical for this asset class. As we see repayments start to recur at a more normal cadence, these realization fees and other income associated with the loans will become more recurring and more consistently benefit our quarterly earnings. At year-end, SLRC had $104 million of unfunded life science commitments, which are available for the borrowers upon reaching certain milestones. We expect these to be drawn in future quarters to fund continued growth of our life science portfolio. In addition, life science team has a robust pipeline of new opportunities, which we also expect to fuel growth this year. The weighted average yield of this portfolio is just under 11% at cost. This excludes any success fees and warrants. In conclusion, SLRC's portfolio activity in the fourth quarter represents a continuation of our investment themes, focusing new origination activity on first lien cash flow loans that are operating in defensive sectors, increasing our investment in specialty finance assets where we are able to get tighter structures and more attractive risk-adjusted returns, and also growing our investments alongside existing portfolio companies by committing to delayed draw facilities which fund acquisitions over future quarters. Across our strategies, we're seeing a number of attractive investment opportunities. This is reflective of the solid economic rebound and increased middle market sponsor activity. The current market environment provides a great opportunity for us to continue to grow our portfolio this year. At this time, I'll turn the call back to Michael. Thank you, Bruce. In closing, the fourth quarter culminated in a strong year of originations for SLRC. In particular, our Sponsor Finance team capitalized on a strong opportunity set in our core industries. We are optimistic about our earnings growth potential and the opportunity set across each of our investment verticals. With the economic recovery in full swing and our portfolio on solid footing, we are focused on deploying our capital into attractive investment opportunities. Across our investment strategies, which span cash flow, ABL, life sciences, and additional equipment financing and corporate leasing, we are seeing steady origination activity, which should translate into continued portfolio growth in the coming quarters. We believe that we are still in the early innings with substantial runway as financial sponsors deploy record amounts of dry powder and more of the larger businesses we prefer to lend to choose direct financings over syndicated debt markets. These industry tailwinds, combined with the scale of SLRC's investment advisor, should benefit SLRC investors through greater access to upper middle-market cash flow investment opportunities, which, as last year has proven, are better positioned to protect capital than most smaller companies. Additionally, we are reaping the benefits of our scale advantage in our cash flow, life science, and ABL verticals. As I mentioned in my opening remarks, Bruce and I, as co-CEOs, and our independent directors believe that the proposed merger of SLRC and SUNS will increase our ability to deliver shareholder value through capital preservation and increase net investment income per share. We believe that now is the opportune time to merge the two companies, given the benefits of greater scale, expected synergies, and ease of integration resulting from the overlap in their investment focus and the advisors' knowledge of both portfolios. Both companies have healthy balance sheets today, and their portfolios are in excellent shape with strong credit quality, which we believe bodes well for this merger. Additional details about the merger can be found by going to www.proxyvote.com and typing in the control number that was provided in the proxy materials mailed to our shareholders. Once on the site, you can also submit your vote. We encourage you to support the merger by voting for the issuance of common stock. We appreciate your support. At 11:00 A.M. this morning, we'll be hosting an earnings call for the fourth quarter 2021 results of SLR Senior Investment Corp or SUNS. Our ability to provide traditional middle market senior secured financing through this vehicle continues to enhance our origination team's ability to meet our borrowers' capital needs, and we continue to see benefits of this value proposition in our deal flow. We appreciate your time. Operator, would you please open the line for questions? Thank you, and as a reminder to ask a question, simply press star one on your telephone. To withdraw your question, press the hash or pound key. Please stand by while we compile the Q&A roster. First question's from Bryce Rowe with Hovde. Great. Thanks. Good morning. Michael and Bruce, just nice to see the balance sheet leverage continuing to build here. It sounds like pipelines are strong for potential continued balance sheet leverage increases. Any thoughts on how to think about, you know, the build in balance sheet leverage? Certainly not looking for any specifics from a quarterly basis. You know, as you think about the build over, let's say, the next year or two, how do you see it kind of playing out? Yeah, I think there's a couple moving parts, as always, as you can imagine here. First of all, as we talked about with the merger, given Solar being substantially larger than SUNS, it really doesn't impact the leverage materially. The pro forma at year-end of 0.97 for SLR would go down closer to 0.9, but nothing meaningful in terms of impact on the leverage there. I think our goal would be to target the upper end of our range, which, as a reminder, SLR's range for leverage is 0.9-1.25. We'd be targeting the middle to upper end of that by the end of the year. You know, obviously, we don't have visibility on repayment activity, but just on unfunded commitments that we've made, we can firmly see if those end up getting drawn this year, the path to getting towards that upper end. Okay. That's helpful. Then maybe one more from me. Thinking about the income statement and the dividends that are coming from the specialty finance verticals, you know, a couple of them, as you noted, saw some lower volumes during COVID. You're starting to see the portfolios build back up. Just curious how you think about maybe a kind of a rebuild in those, in a few of those dividends coming from the specialty finance verticals. What do you need to see for those, you know, for those dividend streams to kind of build a little bit here? Thanks. Yeah. I think it's really looking at, you know, particularly as you think about the equipment financing businesses, both the leasing as well as equipment finance, we do expect by the end of the year to see some growth there in those portfolios and hopefully therefore in the underlying dividend streams. We do try to smooth them out, as you know, because the earnings are not a straight line on a quarterly basis, but we do look at that over the course of a 12-month period. There's a good backlog in those businesses. The credit solutions business is a little bit more challenging just because to forecast because it is a short duration asset class as opposed to equipment financing and leasing and tends to have a short duration and consistent repayment there. There, I think, you know, it's less likely in the near term, but I do think that there's opportunities as we continue to grow those portfolios. You know, just as a side note, the equipment finance and more so the corporate leasing business has had very strong pipeline, but unfortunately, it's been committed and not yet funded given some of the delays in the supply chain getting equipment to borrowers such that they need our capital to fund the actual purchase or lease. Some of that starts to work through the system. You're gonna see additional growth there. If they were on this call, they'd tell you it's the strongest pipeline they've ever had. You know, as we mentioned at the outset, Michael mentioned, we're very pleased they're over-delivering our original expectations at the time of purchase. I think there's upside, but I think it's something that we're gonna revisit as we get closer to the end of the year. Okay, great. I'll step back out. Appreciate the answers. Thank you for your time. Your next question comes from Mickey Schleien with Ladenburg. Yes, good morning, Bruce and Michael. I want to ask how you feel about your borrowers' revenue and margin trends, given the tight labor markets and rising input costs. How do you feel about their ability to service their debt with the potential rate increases that the Fed's talking about? Yeah, that's a great question. I think the pressure is definitely there. We're not seeing it coming into the P&Ls of our borrowers in a big way yet, but we are expecting to this year. I think, you know, as you can appreciate, as you look across our segments, you know, we're blessed that our ABL businesses, yes, they look to the P&L for liquidity and cash flow to service the debt, but our underwriting thesis is based on the underlying liquidation value of its assets. Our life science businesses used to have no free cash flow and, you know, funds themselves off of additional equity constantly coming in from the VCs and owners. The cash flow business is where we feel that pressure and expect to this year. I think, you know, the best thing one can do is try to mitigate it by being in defensive high free cash flowing sectors, you know, where we're seeing three-to-one interest coverage. You know, maybe that'll come back to more traditional norms of two-to-one interest coverage, but still substantial cushion, particularly when you think about the fact that, A, we're in defensive sectors, B, we are dollar one first lien, so we're gonna be the last guy hurt from that margin pressure that we do expect. Importantly, we have floating rate investments. That gives us a bit of a hedge there too. We are starting to see it come in, Mickey, particularly in some of the service businesses in terms of staffing charges, and the ability to attract personnel and pay up for that personnel. I think that's where we're seeing some margin pressure early days. Again, we really don't see that in most of our segments. We're not in manufacturing where you have other raw material input, inflation that would impact your margins. Yeah, importantly, as you know, today only 20% of our portfolio is in cash flow, and it is concentrated in those industries that really are affected. I think that's a question that I think a lot of, you know, private equity owners who own levered equity or high yield bond buyers who own unsecured debt. I think that's a much greater worry for them than someone who's a senior secured lender like ourselves. Yeah, I appreciate that, Michael. Just one follow-up question from me. I noticed valuation of PPT Management was down quarter to quarter. I do know that, you know, it's moved up and down in the past, but that borrower's in the physical therapy segment, which generally has strong secular trends. So could you just give us some background on what's going on there and what- Sure. drove down its valuation? Yeah. I think that's a great follow-on question to your prior question. That is a business that, to your point, physical therapy. It has a unique and dominant footprint in the tri-state New York metropolitan area, so very attractive from a strategic perspective, which was part of our initial underwriting thesis. We have been invested, as you know, being a longtime supporter of ours in ATI and other physical therapy businesses around the country. This is definitely a business that we see being impacted by increased costs on the staffing side, reflecting some pressure on margins. So we try to reflect that in our mark here. You know, revenues have held up nicely. You know, it ebbed and flowed during COVID, obviously. You know, physical therapy is a business that one needs after certain elective surgeries and activity injuries, et cetera, that you need to rehab from. During COVID lockdowns, a lot of that was deferred. It picked back up in 2021, which is why to your point, you saw the mark recover as the business recovered. As Omicron hit, again, we saw some pullback late last year. That seems to be coming back. Revenue's held up nicely, but we're definitely watching that in terms of margin pressure from staffing costs. Again, I think the fallback is, as a first lien floating rate investor rather than a junior capital or equity investor, is that there's real strategic value for these assets, as you know, across the market, particularly given their presence in the New York metropolitan area, where there are not only several hospitals that do elective surgeries that would lend themselves to physical therapy post-surgery for recovery, but also dense population trips and falls and other need. So we're very focused on the demand drivers here, but I do think we're gonna see some margin pressure as we have recently. Bruce, on PPT, just to follow up. Is the sponsor there? I'm assuming it's sponsored. Do you think they would be more interested in making acquisitions and, you know, doing a roll-up, or would they be more interested in selling to someone else? I think it's too soon to know. You know, they've done both. Our perspective is we like where we sit in the capital structure, we like the strategic value, and we're comfortable whether they, you know, sell it, make more acquisitions, either way, we like where we're positioned. Too soon to know. I think there will be some developments over the next, you know, couple of years here because they have been invested for a few years. appreciate that. That's it for me this morning. Thank you for your time. Thank you, Mickey. Thanks. Your next question comes from Melissa Wedel with JPMorgan. Good morning. Good morning. Hi, I appreciate you taking my questions today. First, I was hoping to touch on sort of the yield trends that you're seeing quarter-over-quarter in cash flow and equipment finance in particular. Wanted to make sure I'm understanding what's happening there, given a decline, you know, a more notable decline quarter-over-quarter in those yields. Is that being driven by spread compression, or is there something else happening? Yeah. Cash flow, I don't think there's been a significant change, although we have put out a number of new investments in cash flow in 2021. As you know, the reality is that the good cash flow loans get repaid rather quickly, which accelerates our returns. We underwrite a yield to expected that is higher than the yield to maturity, but we're reporting yields on a yield to maturity basis, not a yield to expected basis. To step back for a moment, leaving the reporting and accounting aside, we haven't seen much compression. Obviously, we have over the last few years, but in 2021, we really haven't seen much compression because the cash flow deals that came to market by and large and where we invested are focused on, as you know, our core industry groups of healthcare, business services, recurring software, financial services, and tends to be with sponsors who have, you know, rather than just looking for financial engineering to help drive the returns, you know, really organic acquisition growth stories and, you know, spreads have held up very nicely there. We really haven't seen much recent pressure aside from the compression that we saw over the last few years. That seems to have abated in 2021. On the equipment finance side, we definitely just as a strategy are looking to expand our footprint. We're finding that there are some lower yielding assets that, you know, bring pretty attractive risk-adjusted returns. We're expanding the footprint of our equipment finance business to include some lower yielding, lower risk assets to help us scale that portfolio, which on a net basis, because as you know, equipment finance is a cyclical sector apart from our corporate leasing, which is to investment grade borrowers. The equipment finance is to small borrowers against mission-critical equipment. There is the one part of our platform that has a little bit of cyclicality, and we've been mitigating that by, yes, doing a little bit, lower risk, lower yield, larger borrower investments. Okay, that's really helpful. It sounds like your outlook, if you will, given the strategy, especially, you know, in equipment finances, maybe for some yield stability, based off of sort of recent levels. Yes. Okay. Was also hoping to get an update on American Teleconferencing Services. It looked like there might have been a bit of a markdown on that one during the quarter. Yeah. was just hoping to get an update. Sure. Thanks. Yep, great question. Yeah, as you know, that is the one investment we have on non-accrual. I guess if there's good news, the good news is, unfortunately, it's the one non-accrual at SUNS as well. Both portfolios have a little bit of this asset on a rel- val basis. The silver lining I would say on this one is that we and the lender group took control of the business middle of last year as we were heading into the third quarter. And as you know, in difficult investments, the first step is really understanding what you own. As a lender, you know what you know, and you know what you're told. You're not, you know, on the board, and you're not talking to management every day and under the hood at that granular level. We did take control. That's a great position for us. You know, we're control freaks and information obsessed. We know what we own there. We think we have it marked for recovery. We've got a great management team in there focused on turning it around, stabilizing it. They've been in there for a few months and have had a dramatic impact already. We thought there was a time where the lender group may have to put in some liquidity working capital. That's not the need. They've been able to really shore up the liquidity of the business, and now we'll spend 2022 really mapping out the paths to recovery. It's a collection of divisions. Some may best be monetized by selling, some may best be monetized by growing. As I mentioned, we think it's marked for recovery. We like where we stand. Obviously, it's never good to have an investment on non-accrual and to mark it down. You know, as we have done in the past, one or two times when need be, given our private equity backgrounds and orientation, Michael in particular and the rest of the team, we have taken control of assets, put in management teams, and been patient to optimize our recovery, and that's the game plan for this one. All right. Ladies and gentlemen, if you have a question, simply press star one on your telephone. Next question is from Paul Johnson with KBW. Yeah. Good morning, guys. Thanks for taking my questions. Good morning. My first question is just on your guys' ROE. It's been running around 7% or thereabouts for the last year or two. I understand we obviously have the base fee reduction coming up after the merger, as well as some other potential cost savings there, but also maybe a potentially lower overall yield just with the combination of the two books. I'm just wondering, trying to get your thoughts, you know, where do you think, you know, your ROE could eventually get to following the merger? Yeah, I would just one clarification. Great question. The book at Solar Senior, to your point, does have some lower yielding cash flow assets, but it also has some high yielding, ABL, specialty finance businesses. Coincidentally, the yield is pretty close to the Solar yield of 10% on a blended basis. Similar SLR, I'm sorry. Similar SLR, SUNS balances that or barbells it by having lower yielding cash flow. It's just their cash flow assets are sub 7%, whereas SLR's are 8%. On a blended basis, we think that there is no dilution in terms of the yield across the combined portfolio post merger. I think the target, you know, should be thought of as something over 8%. Okay. Great. That's good to hear. Thanks for that. Lastly, I'm just curious maybe to get your thoughts on how you kind of see inflation or just the prospect of rising rates and a higher forward LIBOR curve flowing through your sort of various verticals, maybe more specifically, you know, the equipment finance and leasing and asset-backed verticals. You know, do you expect you know any pressure on asset values within those verticals, or even just you know how you expect that to impact you know demand for those types of funding? Yeah. You know, look, great question. As you know, across the majority of our verticals, we're floating rate. We are first lien across all verticals, so that's a great hedge there. Equipment finance does have fixed rate assets, but also, as you know, we have a fair amount of fixed rate borrowings, including the ABL, the liabilities we just put on in Q1 and Q3 of last year. So we've always been very heavy. I wanna say we're probably over 60% fixed rate in terms of our liability structure. I also think from an inflation perspective, you know, we are seeing values recover from the depths of COVID, and we're seeing borrowers both in equipment financing and corporate leasing extending their leases with us, which is giving us a nice pop on our earnings as we extend those leases because they're struggling to get new equipment to replace the equipment they're already leasing from us. We feel like we're pretty well hedged there. Okay. Appreciate that. It's very helpful. That's all for me today. Thank you. Your next question is from Robert Dodd with Raymond James. Hi, guys. On Michael, I think you made a comment about an active portfolio of acquisition opportunities. Would you say that pipeline, that potential is more elevated than normal, or is that just kind of your normal level of looking at add-ons? I mean, looking at Kingsbridge, obviously very successful acquisition, great return on invested capital, et cetera. I mean, you know, is that the kind of return that's potentially in the hopper for additional acquisitions or any more color there? I would say in general, our pipeline is definitely more active now than it was in the fourth quarter. It's definitely picked up. I'd say generally, we target kind of ROE on the specialty finance acquisitions of, you know, 10%-13%, depending on the situation. That could be in the form of something like Kingsbridge, which is a brand new platform acquisition or an add-on acquisition like we've done for the business credit division of SUNS. One of the things that we're excited about is that by merging the two entities, it makes us a better acquirer. What I mean by that is, you know, when we've had two separate companies to buy for, it's imposed constraints, primarily on size. For example, with SUNS, market cap of $230 million, it's been constrained in doing add-on acquisitions by virtue that certain things have been too large for it. As the combined entity with over $2 billion of assets and over $1 billion of NAV, we have a much greater balance sheet from which to acquire from. That is part of the strategic rationale for having this merger take place. [crosstalk] I would say Robert, the broad commercial finance M&A pipeline, leaving aside our specific interest, although we are very interested given that we have a number of different platforms that we can add to, as well as looking at new platforms. I would just say it's been a very active marketplace out there right now. There's a lot of guys coming to market. You know, as you know, also one of our lending verticals is our lender finance business, where historically we've lent to specialty finance companies, which potentially have led to acquisitions. That's how Kingsbridge came about. We have a $80 million loan outstanding to it, to the private equity sponsor for over two years. We've actually added to our team fairly significantly this past year. We added two senior individuals who are on the origination side, sourcing not just potential acquisitions but also loans as well. I'd say our pipeline on our lending business is fairly strong. Got it. Thank you. I mean, put air quotes around this. Are there any holes in your platform? I mean, as you've expanded these verticals, I mean, there's potential, especially when you bring everything under one roof, larger umbrella, right? So there are intended to be sourcing synergies and things like that. Are there, you know, obvious holes that you found in terms of like sourcing opportunities that, you know, your existing portfolio companies see, but that you don't have an offering in? That's a great question. I would say we keep learning more and more about these niche commercial finance businesses and marketplaces, as we go. You know, as we talked about over at Solar Senior, we have a business that is focused on working capital financing, both in terms of ABL revolving lines of credit, but also in terms of factoring. Well, last year, they did an add-on acquisition of a factoring business in digital media, which is an industry extension from a core competency they already had. What I mean by this example, Robert, is that there are a number of these. These are very fragmented businesses. There are regional expansions, there are industry-focused expansions, that gives us a lot of white space for the existing platforms that, you know, is it a new business or is it an extension? It's something we're not doing today, but we're building on a core competency to leverage off of. I think, you know, to Michael's point, we often will use as we have to get into life sciences, to get into Kingsbridge, to get into so many things in specialty finance. We use our lender finance R&D laboratory to lend into these asset classes prior to finding something that we might wanna own control of. I think one of the areas that we continue to sniff around and make some investments, we made one in the fourth quarter, is ways to look at lower risk, yet differentiated, niche real estate opportunities from a lending perspective, where we can try to, you know, mitigate a lot of the inherent cyclicality in the asset class, maybe look at shorter duration assets that give us comfort. So that is an area that, you know, we continue to focus on ways that might be, you know, consistent with A, our D&A and B, our risk-adjusted return profile. Got it. Thank you. One last one for me. On the dividend, I think we should after the merger, the plan is to go to a monthly instead of quarterly. Any color you can give on why that decision was made? I mean, obviously it was a board decision, but we have a couple of board members here on the call. Obviously here, the simple math, 41 doesn't divide by three. It doesn't have to be about a number, but you know, any comment you can give around that, about that? Well, I was gonna say, I guess we'll just have to increase it. All kidding aside, I think it was, you know, something that just for simplicity purposes, although Rich would not call it simplifying his life, getting a dividend out every month. I think, you know, as you know, a number of our investors just like the consistency- Mm-hmm. of a payment schedule on a monthly basis. We thought it might be a good time to adopt it. The current intent is to take the $0.41 and divide it by three. Okay. Fair enough. Thank you. Thank you. Thank you. Your next question comes from Casey Alexander with Compass Point. Well, that's the risk of coming in at minute 56, is that I was gonna ask about lender finance as a pipeline for acquisitions, and I was gonna ask about the dividend. My questions have been answered. Thanks. Perfect. We knew you were gonna ask that, so we read your mind. Thank you. Thanks, Casey. I'm not showing any further questions in the queue, sir. Well, we appreciate all your support and, again, for those of you who own shares, we'd appreciate you voting, so we can close our merger, and we'll talk to whoever is gonna be on our SUNS call in three minutes. Thank you. Bye-bye. This concludes today's conference call. Thank you for participating, and you may now disconnect.